Physical Characterization of the "Immunosignaturing Effect"

被引:42
作者
Stafford, Phillip [1 ]
Halperin, Rebecca [1 ]
Legutki, Joseph Bart [1 ]
Magee, Dewey Mitchell [1 ]
Galgiani, John [2 ]
Johnston, Stephen Albert [1 ]
机构
[1] Arizona State Univ, Ctr Innovat Med, Biodesign Inst, Tempe, AZ 85287 USA
[2] Univ Arizona, Dept Immunol, Valley Fever Ctr Excellence, Tucson, AZ 85719 USA
关键词
IN-VIVO; PARANEOPLASTIC SYNDROMES; B-CELLS; AUTOANTIBODIES; IDENTIFICATION; PHAGE; BIOMARKERS; EPITOPES; CANCER; GAD;
D O I
10.1074/mcp.M111.011593
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Identifying new, effective biomarkers for diseases is proving to be a challenging problem. We have proposed that antibodies may offer a solution to this problem. The physical features and abundance of antibodies make them ideal biomarkers. Additionally, antibodies are often elicited early in the ontogeny of different chronic and infectious diseases. We previously reported that antibodies from patients with infectious disease and separately those with Alzheimer's disease display a characteristic and reproducible "immunosignature" on a microarray of 10,000 random sequence peptides. Here we investigate the physical and chemical parameters underlying how immunosignaturing works. We first show that a variety of monoclonal and polyclonal antibodies raised against different classes of antigens produce distinct profiles on this microarray and the relative affinities are determined. A proposal for how antibodies bind the random sequences is tested. Sera from vaccinated mice and people suffering from a fugal infection are individually assayed to determine the complexity of signals that can be distinguished. Based on these results, we propose that this simple, general and inexpensive system could be optimized to generate a new class of antibody biomarkers for a wide variety of diseases. Molecular & Cellular Proteomics 11: 10.1074/mcp.M111.011593, 1-14, 2012.
引用
收藏
页数:14
相关论文
共 43 条
[1]  
Adda CG, 2002, COMB CHEM HIGH T SCR, V5, P1
[2]  
af Geijersstam V, 1998, J INFECT DIS, V177, P1710, DOI 10.1086/517428
[3]   Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective [J].
Amur, Shashi ;
Frueh, Felix W. ;
Lesko, Lawrence J. ;
Huang, Shiew-Mei .
BIOMARKERS IN MEDICINE, 2008, 2 (03) :305-311
[4]   Development of autoantibodies before the clinical onset of systemic lupus erythematosus [J].
Arbuckle, MR ;
McClain, MT ;
Rubertone, MV ;
Scofield, RH ;
Dennis, GJ ;
James, JA ;
Harley, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (16) :1526-1533
[5]   Maturation of the humoral autoimmune response to epitopes of GAD in preclinical childhood type 1 diabetes [J].
Bonifacio, E ;
Lampasona, V ;
Bernasconi, L ;
Ziegler, AG .
DIABETES, 2000, 49 (02) :202-208
[6]   Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids [J].
Bowman, CC ;
Clements, JD .
INFECTION AND IMMUNITY, 2001, 69 (03) :1528-1535
[7]   High-density peptide arrays [J].
Breitling, Frank ;
Nesterov, Alexander ;
Stadler, Volker ;
Felgenhauer, Thomas ;
Bischoff, F. Ralf .
MOLECULAR BIOSYSTEMS, 2009, 5 (03) :224-234
[8]   Phage display epitope mapping of human neutrophil flavocytochrome b558 -: Identification of two juxtaposed extracellular domains [J].
Burritt, JB ;
DeLeo, FR ;
McDonald, CL ;
Prigge, JR ;
Dinauer, MC ;
Nakamura, M ;
Nauseef, WM ;
Jesaitis, AJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (03) :2053-2061
[9]   Managing and exploiting stress in the antibody factory [J].
Cenci, Simone ;
Sitia, Roberto .
FEBS LETTERS, 2007, 581 (19) :3652-3657
[10]   Evaluation of Biological Sample Preparation for Immunosignature-Based Diagnostics [J].
Chase, Brian Andrew ;
Johnston, Stephen Albert ;
Legutki, Joseph Barten .
CLINICAL AND VACCINE IMMUNOLOGY, 2012, 19 (03) :352-358